Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 38.09
ARWR's Cash-to-Debt is ranked lower than
51% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. ARWR: 38.09 )
Ranked among companies with meaningful Cash-to-Debt only.
ARWR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 33.21 Max: No Debt
Current: 38.09
Equity-to-Asset 0.68
ARWR's Equity-to-Asset is ranked higher than
54% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ARWR: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
ARWR' s Equity-to-Asset Range Over the Past 10 Years
Min: -39.56  Med: 0.75 Max: 0.95
Current: 0.68
-39.56
0.95
Interest Coverage N/A
ARWR's Interest Coverage is ranked lower than
52% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ARWR: N/A )
Ranked among companies with meaningful Interest Coverage only.
ARWR' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: N/A Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: -3.28
Beneish M-Score: 10.52
WACC vs ROIC
12.16%
-668.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -1725.51
ARWR's Operating Margin % is ranked lower than
82% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. ARWR: -1725.51 )
Ranked among companies with meaningful Operating Margin % only.
ARWR' s Operating Margin % Range Over the Past 10 Years
Min: -51736.08  Med: -8478.97 Max: -520.49
Current: -1725.51
-51736.08
-520.49
Net Margin % -1663.95
ARWR's Net Margin % is ranked lower than
82% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. ARWR: -1663.95 )
Ranked among companies with meaningful Net Margin % only.
ARWR' s Net Margin % Range Over the Past 10 Years
Min: -51723.42  Med: -10738.97 Max: -513.78
Current: -1663.95
-51723.42
-513.78
ROE % -88.59
ARWR's ROE % is ranked lower than
74% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. ARWR: -88.59 )
Ranked among companies with meaningful ROE % only.
ARWR' s ROE % Range Over the Past 10 Years
Min: -225.02  Med: -94.07 Max: -28.66
Current: -88.59
-225.02
-28.66
ROA % -66.09
ARWR's ROA % is ranked lower than
74% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ARWR: -66.09 )
Ranked among companies with meaningful ROA % only.
ARWR' s ROA % Range Over the Past 10 Years
Min: -154.73  Med: -77.87 Max: -22.16
Current: -66.09
-154.73
-22.16
ROC (Joel Greenblatt) % -730.98
ARWR's ROC (Joel Greenblatt) % is ranked lower than
56% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. ARWR: -730.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARWR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11843.37  Med: -1977.04 Max: -584.83
Current: -730.98
-11843.37
-584.83
3-Year Revenue Growth Rate -37.00
ARWR's 3-Year Revenue Growth Rate is ranked lower than
80% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. ARWR: -37.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARWR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -51.5 Max: 64.8
Current: -37
0
64.8
3-Year EBITDA Growth Rate 10.50
ARWR's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. ARWR: 10.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARWR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56.2  Med: -12.5 Max: 190.2
Current: 10.5
-56.2
190.2
3-Year EPS without NRI Growth Rate 1.10
ARWR's 3-Year EPS without NRI Growth Rate is ranked higher than
53% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. ARWR: 1.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ARWR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -75.1  Med: -7.3 Max: 162.1
Current: 1.1
-75.1
162.1
GuruFocus has detected 3 Warning Signs with Arrowhead Pharmaceuticals Inc $ARWR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARWR's 10-Y Financials

Financials (Next Earnings Date: 2017-05-06 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ARWR Guru Trades in Q1 2016

Paul Tudor Jones Sold Out
» More
Q2 2016

ARWR Guru Trades in Q2 2016

Steven Cohen 256,101 sh (New)
» More
Q3 2016

ARWR Guru Trades in Q3 2016

Steven Cohen 8,500 sh (-96.68%)
» More
Q4 2016

ARWR Guru Trades in Q4 2016

Paul Tudor Jones 305,857 sh (New)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2834
Compare:AMEX:PLX, NAS:MDWD, NAS:LPTX, NAS:SBBP, NAS:ALBO, OTCPK:HSDT, OTCPK:NURPF, OTCPK:PHGUF, NAS:EVGN, NAS:ABUS, NAS:QURE, AMEX:PFNX, OTCPK:ATVBF, OTCPK:INNMF, OTCPK:PAIOF, NAS:GEMP, NAS:GLYC, NAS:NVIV, NAS:MRTX, AMEX:AST » details
Traded in other countries:HDP1.Germany,
Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company's drug candidate ARC-520 is designed to treat chronic hepatitis B infection.

Arrowhead Research is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Ratios

vs
industry
vs
history
PB Ratio 1.48
ARWR's PB Ratio is ranked higher than
84% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ARWR: 1.48 )
Ranked among companies with meaningful PB Ratio only.
ARWR' s PB Ratio Range Over the Past 10 Years
Min: 0.94  Med: 4.76 Max: 71.58
Current: 1.48
0.94
71.58
PS Ratio 30.17
ARWR's PS Ratio is ranked lower than
66% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. ARWR: 30.17 )
Ranked among companies with meaningful PS Ratio only.
ARWR' s PS Ratio Range Over the Past 10 Years
Min: 4.04  Med: 185.7 Max: 4132.5
Current: 30.17
4.04
4132.5
Current Ratio 2.87
ARWR's Current Ratio is ranked lower than
63% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ARWR: 2.87 )
Ranked among companies with meaningful Current Ratio only.
ARWR' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.34 Max: 302.61
Current: 2.87
0.01
302.61
Quick Ratio 2.87
ARWR's Quick Ratio is ranked lower than
59% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ARWR: 2.87 )
Ranked among companies with meaningful Quick Ratio only.
ARWR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 4.71 Max: 302.61
Current: 2.87
0.01
302.61
Days Sales Outstanding 4.89
ARWR's Days Sales Outstanding is ranked higher than
93% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. ARWR: 4.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARWR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.12  Med: 82.79 Max: 1982.84
Current: 4.89
1.12
1982.84

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -29.00
ARWR's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ARWR: -29.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARWR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -598.6  Med: -29 Max: 0
Current: -29
-598.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.57
ARWR's Price-to-Net-Cash is ranked higher than
80% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. ARWR: 2.57 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ARWR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.05  Med: 7.04 Max: 103.64
Current: 2.57
0.05
103.64
Price-to-Net-Current-Asset-Value 2.38
ARWR's Price-to-Net-Current-Asset-Value is ranked higher than
81% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. ARWR: 2.38 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARWR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.04  Med: 7.13 Max: 70.89
Current: 2.38
0.04
70.89
Price-to-Tangible-Book 1.87
ARWR's Price-to-Tangible-Book is ranked higher than
82% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ARWR: 1.87 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARWR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.04  Med: 6.46 Max: 54.5
Current: 1.87
0.04
54.5
Price-to-Median-PS-Value 0.16
ARWR's Price-to-Median-PS-Value is ranked higher than
95% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ARWR: 0.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARWR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 0.53 Max: 19.96
Current: 0.16
0.03
19.96
Earnings Yield (Greenblatt) % -176.07
ARWR's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. ARWR: -176.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARWR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1217.63  Med: 0 Max: 1793.66
Current: -176.07
-1217.63
1793.66

More Statistics

Revenue (TTM) (Mil) $4.48
EPS (TTM) $ -1.18
Beta1.32
Short Percentage of Float15.05%
52-Week Range $1.20 - 8.22
Shares Outstanding (Mil)74.57

Analyst Estimate

Sep17 Sep18
Revenue (Mil $) 0 0
EPS ($) -0.81 -0.73
EPS without NRI ($) -0.81 -0.73
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:ARWR

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : March 27, 2017 Mar 27 2017
ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 23 2017
Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement Mar 23 2017
Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q1, 2017 By the Numbers : March 21,... Mar 21 2017
SBPH: 2016 Results Sustaining Continued HBV/STING Development Feb 27 2017
These 5 Stocks Under $10 Could Explode Higher Feb 16 2017
ARROWHEAD PHARMACEUTICALS, INC. Financials Feb 10 2017
Edited Transcript of ARWR earnings conference call or presentation 6-Feb-17 9:30pm GMT Feb 06 2017
ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 06 2017
Arrowhead Research reports 1Q loss Feb 06 2017
Arrowhead Research reports 1Q loss Feb 06 2017
Arrowhead Reports Fiscal 2017 First Quarter Results Feb 06 2017
Q1 2017 Arrowhead Pharmaceuticals Inc Earnings Release - After Market Close Feb 06 2017
Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on... Feb 01 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results Jan 30 2017
Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a... Jan 20 2017
IMPORTANT ARWR SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit... Jan 14 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Arrowhead... Jan 13 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of... Jan 13 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead... Jan 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)